β-Amyloid and Neprilysin Computational Studies Identify Critical Residues Implicated in Binding Specificity
暂无分享,去创建一个
[1] D. Teplow,et al. Structural and kinetic features of amyloid beta-protein fibrillogenesis. , 1998, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[2] D. Selkoe,et al. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. , 2003, Annual review of pharmacology and toxicology.
[3] F. Diederich,et al. Second-Generation Inhibitors for the Metalloprotease Neprilysin Based on Bicyclic Heteroaromatic Scaffolds: Synthesis, Biological Activity, and X-ray Crystal Structure Analysis , 2005 .
[4] M. Citron,et al. Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.
[5] A. LeBlanc,et al. Selective cytotoxicity of intracellular amyloid β peptide1–42 through p53 and Bax in cultured primary human neurons , 2002, The Journal of cell biology.
[6] L. Hersh,et al. Insulysin Hydrolyzes Amyloid β Peptides to Products That Are Neither Neurotoxic Nor Deposit on Amyloid Plaques , 2000, The Journal of Neuroscience.
[7] P. Kollman,et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.
[8] P. Coric,et al. Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities. , 2000, Journal of medicinal chemistry.
[9] S. Love,et al. A&bgr;-Degrading Enzymes: Potential for Treatment of Alzheimer Disease , 2011, Journal of neuropathology and experimental neurology.
[10] N. Belyaev,et al. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. , 2008, Current Alzheimer research.
[11] T. Iwatsubo,et al. Neprilysin Degrades Both Amyloid β Peptides 1–40 and 1–42 Most Rapidly and Efficiently among Thiorphan- and Phosphoramidon-sensitive Endopeptidases* , 2001, The Journal of Biological Chemistry.
[12] L. Serpell,et al. Molecular structure of a fibrillar Alzheimer's A beta fragment. , 2000, Biochemistry.
[13] L. Hersh,et al. Circulating neprilysin clears brain amyloid , 2010, Molecular and Cellular Neuroscience.
[14] Bethany M. Wootton,et al. The Acceptability of Internet-Based Treatment and Characteristics of an Adult Sample with Obsessive Compulsive Disorder: An Internet Survey , 2011, PloS one.
[15] L. Hersh,et al. Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[16] Dan S. Tawfik,et al. The 'evolvability' of promiscuous protein functions , 2005, Nature Genetics.
[17] L. Hersh,et al. Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer's disease , 2009, Journal of neuroscience research.
[18] Judianne Davis,et al. Structural conversion of neurotoxic amyloid-β(1–42) oligomers to fibrils , 2010, Nature Structural &Molecular Biology.
[19] B. Matthews,et al. Thiorphan and retro-thiorphan display equivalent interactions when bound to crystalline thermolysin. , 1989, Biochemistry.
[20] L. Hersh,et al. Neprilysin and amyloid beta peptide degradation. , 2008, Current Alzheimer research.
[21] S. Howell,et al. Neutral endopeptidase can hydrolyze β-amyloid(1–40) but shows no effect on β-amyloid precursor protein metabolism , 1995, Peptides.
[22] L. K. Baker,et al. Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.
[23] T. Saido,et al. Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.
[24] L. Hersh,et al. Active Site Mutations Change the Cleavage Specificity of Neprilysin , 2012, PloS one.
[25] S. Manzetti. Computer modeling and nanosecond simulation of the enzyme–substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases , 2003, Journal of molecular modeling.
[26] B. Roques,et al. Evidence that Asn542 of neprilysin (EC 3.4.24.11) is involved in binding of the P2' residue of substrates and inhibitors. , 1995, The Biochemical journal.
[27] Nikos Dimitropoulos,et al. A Computational Approach to the Study of the Binding Mode of Dual ACE/NEP Inhibitors , 2010, J. Chem. Inf. Model..
[28] T. Saido,et al. Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.
[29] E. Masliah,et al. Peripheral Delivery of a CNS Targeted, Metalo-Protease Reduces Aβ Toxicity in a Mouse Model of Alzheimer's Disease , 2011, PloS one.
[30] J. Morris,et al. Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.
[31] E Harper,et al. On the size of the active site in proteases: pronase. , 1972, Biochemical and biophysical research communications.
[32] I. Hamley. The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. , 2012, Chemical reviews.
[33] M. Fournié-Zaluski,et al. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. , 1993, Pharmacological reviews.
[34] I. Verma,et al. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. , 2008, The American journal of pathology.
[35] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[36] H. Mizukami,et al. Presynaptic Localization of Neprilysin Contributes to Efficient Clearance of Amyloid-β Peptide in Mouse Brain , 2004, The Journal of Neuroscience.
[37] S. Love,et al. Changes with Age in the Activities of β‐Secretase and the Aβ‐Degrading Enzymes Neprilysin, Insulin‐Degrading Enzyme and Angiotensin‐Converting Enzyme , 2010, Brain pathology.
[38] D. Dickson,et al. Expression and functional profiling of neprilysin, insulin‐degrading enzyme, and endothelin‐converting enzyme in prospectively studied elderly and Alzheimer’s brain , 2010, Journal of neurochemistry.
[39] M. Fournié-Zaluski,et al. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[40] Araz Jakalian,et al. Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: I. Method , 2000 .
[41] L. Hersh,et al. Analysis of the importance of arginine 102 in neutral endopeptidase (enkephalinase) catalysis. , 1992, The Journal of biological chemistry.
[42] Dominic M. Walsh,et al. Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.
[43] H. Huang,et al. The correlation between neurotoxicity, aggregative ability and secondary structure studied by sequence truncated Aβ peptides , 2007, FEBS letters.
[44] D. Selkoe,et al. Aggregation and catabolism of disease-associated intra-Aβ mutations: reduced proteolysis of AβA21G by neprilysin , 2008, Neurobiology of Disease.
[45] B. Roques,et al. Structural analysis of neprilysin with various specific and potent inhibitors. , 2004, Acta crystallographica. Section D, Biological crystallography.
[46] M. Cascio,et al. Neprilysin Inhibitors Provide Insight into its Specificity and Therapeutic Potential , 2014 .
[47] D. Selkoe,et al. Kinetics of Amyloid β-Protein Degradation Determined by Novel Fluorescence- and Fluorescence Polarization-based Assays* , 2003, Journal of Biological Chemistry.
[48] T. Saido,et al. Reply to: 'Clearance of amyloid β-peptide from brain: transport or metabolism?' , 2000, Nature Medicine.
[49] C. Oefner,et al. Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV. , 2007, Acta crystallographica. Section D, Biological crystallography.
[50] E. Capetillo-Zarate,et al. Impaired β-Amyloid Secretion in Alzheimer's Disease Pathogenesis , 2011, The Journal of Neuroscience.
[51] I. Hakker,et al. Overexpression of Neprilysin Reduces Alzheimer Amyloid-β42 (Aβ42)-induced Neuron Loss and Intraneuronal Aβ42 Deposits but Causes a Reduction in cAMP-responsive Element-binding Protein-mediated Transcription, Age-dependent Axon Pathology, and Premature Death in Drosophila* , 2008, Journal of Biological Chemistry.
[52] D. Selkoe,et al. Reducing Amyloid Plaque Burden via Ex Vivo Gene Delivery of an Aβ-Degrading Protease: A Novel Therapeutic Approach to Alzheimer Disease , 2007, PLoS medicine.
[53] D. Owen,et al. Synthesis and evaluation of heteroarylalanine diacids as potent and selective neutral endopeptidase inhibitors. , 2011, Bioorganic & medicinal chemistry letters.
[54] F. Gage,et al. Neprilysin regulates amyloid β peptide levels , 2007, Journal of Molecular Neuroscience.
[55] Y. Lyubchenko,et al. Residues 17–20 and 30–35 of beta‐amyloid play critical roles in aggregation , 2004, Journal of neuroscience research.
[56] T. Saido,et al. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Aβ to physiologically relevant proteolytic degradation , 2003, The Lancet.
[57] B. de Strooper. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. , 2010, Physiological reviews.
[58] Kenjiro Ono,et al. Structure–neurotoxicity relationships of amyloid β-protein oligomers , 2009, Proceedings of the National Academy of Sciences.
[59] Paul Labute,et al. Variability in docking success rates due to dataset preparation , 2012, Journal of Computer-Aided Molecular Design.
[60] A three-dimensional construction of the active site (region 507-749) of human neutral endopeptidase (EC.3.4.24.11). , 1999, Protein engineering.
[61] D. Coates,et al. The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.
[62] Heike Wulff,et al. Amyloid-β Protein Oligomer at Low Nanomolar Concentrations Activates Microglia and Induces Microglial Neurotoxicity* , 2010, The Journal of Biological Chemistry.
[63] Lars Olsen,et al. Binding affinities in the SAMPL3 trypsin and host–guest blind tests estimated with the MM/PBSA and LIE methods , 2012, Journal of Computer-Aided Molecular Design.
[64] L. Serpell,et al. Molecular Structure of a Fibrillar Alzheimer's Aβ Fragment† , 2000 .
[65] F. Liu,et al. A novel system for in vivo neprilysin gene delivery using a syringe electrode , 2010, Journal of Neuroscience Methods.
[66] M. Goedert,et al. A Century of Alzheimer's Disease , 2006, Science.
[67] Immunology and immunotherapy of Alzheimer's disease , 2006, Nature Reviews Immunology.
[68] K. Tanzawa,et al. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[69] B. Strooper. Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process , 2010 .
[70] A. D'Ursi,et al. Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. , 2002, European journal of biochemistry.
[71] F. Winkler,et al. Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. , 2000, Journal of molecular biology.
[72] B. Roques,et al. Differences in the structural requirements for selective interaction with neutral metalloendopeptidase (enkephalinase) or angiotensin-converting enzyme. Molecular investigation by use of new thiol inhibitors. , 1984, European journal of biochemistry.
[73] S. Howell,et al. Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. , 1995, Peptides.
[74] Evidence by site-directed mutagenesis that arginine 203 of thermolysin and arginine 717 of neprilysin (neutral endopeptidase) play equivalent critical roles in substrate hydrolysis and inhibitor binding. , 1997, Biochemistry.
[75] F. Gage,et al. Neprilysin regulates amyloid Beta peptide levels. , 2004, Journal of molecular neuroscience : MN.